INTRODUCTION
Hepatitis C virus is a major health problem throughout the world. The WHO estimates about 200 million people of those infected with HCV, 80% develops chronic hepatitis C infection [1] .
More than 90% of HCV isolates from Egyptian patients are of the genotype 4 variant Egypt has the highest world wide prevalence of HCV (10-20%) [2] .
Antiviral therapy for CHC has many goals, the primary goal is durable viral decrease as evidenced by the absence of HCV RNA in the serum (virological response), the second goal is the reduction of liver damage as determined by either persistently normal ALT (biochemical response) or improved liver biopsy. (Histological response) . Antiviral therapy will delay or prevent cirrhosis, HCC, liver transplantation and death, as well as to prevent the viral spread to other persons and improving the patient's quality of life [3] .
INF was the only therapeutic opinion until the mid-1990s. RBV added to INF resulted in improvement of SVR rates (8 to 42%) in patients with genotype 4 infection [4] .
Modification of the therapeutic molecules of INF through the attachment of polyethylene glycol (PEG) moieties (pegylation) is a common approach to optimize delivery of the drug and to avoid large fluctuating serum concentrations and the inconvenient dosing regimens associated with the standard INF-. Two PEG-modified INFs have been approved for the treatment of CHC which are (PEG-INF2a and 2b). the current treatment of CHC is the combination of PEG-INF and RBV [5] .
Nitazoxanid is the first member of thiazolides, anti-infective role which has an oral agent with no major side effects and licensed in the USA in treatment of cryptosporidium parvum and giardia lamblia [6] .
A serendipitous observation during drug development revelaed that some patients with cryptosporidium and AIDS who are coinfected with HCV or HBV, had a reduction in serum ALT during therapy. NTZ induces double stranded RNA activated protein kinase (PKR) phosphorylation, which results in increased intracellular concentration of phosphrylated factor 2 [7] .
Aim of the work :
The aim of this work is to study impact of NTZ in addition to PEG-2a and RBV on virological responses in patients with CHC.
PATIENTS AND METHODS
The present study was conducted in Tropical Medicine Department Zagazig University Hospital. This work comprised 100HCV patients attending the out patient clinics.
All patients were divided into the following groups:
Group (A): 30 patients received the SOC, PEG-INF-2a 180/µg once weekly and RBV (1000-1200mg) based on body weight .
Group (B):
30 patients received NTZ 500mg tablet twice daily for 4 weeks lead-in phase followed by NTZ of the same dose plus PEG INF-2a (180µg once weekly) and RBV (1000-1200mg) for another 24 weeks. Patients in group A and B stopped treatment when EVR is not achieved as cost-effectiveness in crucial to maximize the health gain achieved in Egypt with the highest prevalence of HCV which is considered a heavy economic burden.
Group (C): 40 patients
received NTZ montherapy 500mg tablet twice daily for 24 weeks.
All patients fulfilled the inclusion criteria which are age 18 years or older normal complete blood picture, normal kidney function tests, thyroid stimulating hormone is within normal level, positive HCV antibody and HCV-RNA with no contraindication to liver biopsy, if liver biopsy >F1 with elevated liver enzymes, if > F2 with normal liver enzymes, alpha fetoprotein <100 IUml, female patients participating adequate contraception. All patients who are pregnant female, lactating, decompensate liver cirrhosis, active epileptic fits, ischemic heart disease, chronic renal failure, autoimmune disease, retinal abnormality severe psychiatric condition or with BMI> 35 were excluded from the study. All patients underwent the following test:
• Full history taking and through clinical examination.
• BMI was calculated as weight / height (m2) <30 • Complete blood picture.
• Liver, kidney function tests, fasting, post prandial blood glucose level.
• Abdominal ultrasonography using aloka SSD-500.
• Feto protein, pregnancy test, antinuclear antibody, thyroid stimulating hormone, ECG, funds examination, HCV antibody by Eliza method.
• Quantitative PCR for HCV at week, 0, 12, 24 was done by cobas amplicor HCV monitor test (HCV, V2.0 Roche Brungburg USA).
• Liver biopsy and fibrosis was evaluated using the metavir scoring system a scale f0-F4: f0 = no-fibrosis, F1= portal tract expansion, F2=less than 50% bridging fibrosis, F3=more than 50% bridging fibrosis without cirrhosis, F4= established cirrhosis .
• The grading of activity was classified as: A0, no histological activity, A1= mild activity, A2= moderate activity, A3= severe activity.
Statistical analysis:
The data were statistically analysed using microstate soft ware program (8) and the following statistical tests were applied :
• Studied "t" test for comparison of means two independent groups.
• ANOVA or f-test for comparison of means of more than two groups.
• Description of quantitative and qualitative variable.
• Chi-square test was to compare qualitative variables.
• Correlation co-efficient test (r-test) was used to rank different variables against each other directly or indirectly.
• P value >0.05 insignificant and P< 0.01 highly significant. 
RESULTS

DISCUSSION
The WHO estimates that about 200 million people were infected with HCV of those infected with HCV 80% develops chronic infection [1] .
INF was the only therapeutic opinion until the mid 1990s RBV was added to INF resulted in improvement of SVR rates (8.42%) in patients with genotype 4 infection [4] .
Nitazoxanide induces double stranded RNA activated protein kinase (PKR) phosporylation, which results in increased intracellular concentration of phosphrylated eukaryotic irritation factor 2 (eIF2), a naturally occurring antiviral intracellular protein and a key mediator of host cell defences against viral infection [7] . It is also believed that it inhibits viral glycoproteins at the posttranslational level. This would prevent the final assembly of the virus before it can exit and affect another.
A serendipitous observation during nitazoxanide development revealed that some patients with cryptosporidiosis and are co-infected with HCV or HIV had a reduction in serum level of ALT during therapy. This observation led to studies of the antiviral activity of NTZ [7] .
This work revealed that patients of group A showed an EVR of 83.3% and 24 week HCV RNA negativity of 76.6%. This is in accordance with the results of El-Makhzangy et al., [10] who conducted a prospective trial to study the response to PEG-INF-2a and RBV in 95 patients with CHC genotype 4 for 48 weeks with results of an EVR of 82% and negative HCV RNA at week 24 achieved in 78% .
El-Zayadi et al. [11] studied the response of CHC patients with genotype 4 to 24 weeks of PEG INF2b and he reported as slightly lowered response rate than those reported in our study. This difference between these results may be attributed to the difference in the demographic characteristics of the patients and the difference between PEG-INF-2a and 2b.
The mechanisms underlying in efficacy between the two PEG-INF- foundation is not clear. However, the structure and the size of the polyether glycol moiety and the means of covalent attachment might affect the pharmacokinetics and parmakodynamics of the two formul-ations, their antiviral activity and the therapy outcome [12] .
Our results are contraverry to those of Dimitroulepoulos [13] who studied the effect of ethnic origin on the treatment outcomes in patients chronically infected with HCV-4 (30 Europeans and 30 Egyptians) and with elevated baseline HCV RNA7800.U/ml. They reported a RVR, EVR and HCV RNA at week 24 in Europeans and Egyptians were (RVR 26.7% vs, 30%) (23.3% vs 17.6%, 13.3% vs 16.7% respectively). This can be explained by the that patients selected in this study were with high baseline HCV RNA and advanced stage of liver histology.
As regard treatment modalities results in our study (group B), the EVR (86.6%, vs 83.3%) for group A) and 24 week PCR negative was (80% vs 76.6% for group A). These results shows that NTZ increase EVR and PCR negativity at week 24.
Rossignol et al. [14] reported a cEVR for the SOC and treatment modalities with NTZ of 70% and 86% respectively while cEVR reported in our study was 80.3% vs 86.6% for the SOC and triple arm respectively while cEVR reported in our study was 80.3% vs 86.6% for the Soc and triple arm respectively.
A possible explanation to the difference between the two studies may be due to that Rossignal et al., conducted a 12 weeks lead in phase compared with a 4 weeks lead in phase with NTZ in our study.
Although, the required duration of NTZ lead-in phase is unknown and 12 weeks was selected as an initial conservative estimate to optimize the potential benefit of NTZ pretreatment. A subsequent study has shown that a 4-week leadin phase may be satisfactory [15, 16] .
Bacon et al. [17] reported a cEVR of 62% which is lower than the present study (86.6%) when studied a 4 weeks lead in phase of NTZ followed by NTZ, PEG-INF-α2a and RBV for 48 weeks. This may be attributed to that genotype 1 is associated with poorer response to antiviral therapy. The most important clinical property of HCV genotype is different susceptibility to INF [18] . It is also possible that demographics, disease related characteristics of the populations that have been studied or pharmacokinetics might account for difference is responses to therapy.
The differences in INF response could be secondary to either differences in the viral virulence and/or replication rate among HCV types, or different in the host immune response to the different HCV genotype .
The poorer response of genotype 4 in Egypt possible because of various subtypes, to different forms of INFs or probably related to an intrinsic resistance to direct antiviral effect of INF [19] .
Egyptian patients infected with HCV genotype 4 after IFN/RBN combination therapy have a high frequency (about double) and significant difference of BCL-2 genotype and allele for nonresponds patients compared with responders as well as healthy controls. This suggests that polymorphism in BCL-2 gene can be augment the current array of predictors of therapeutic response to INF and RBV in HCV type 4 infected patients [20] .
As regard NTZ monotherapy for treatment of CHC in this study two patients (5%) with very low viremia 3.000 and 70.000IU/ml showed cEVR and was instructed to continue on NTZ till the end of 24 week. However, these patients experienced viral breakthrough with positive HCV RNA at the end of the week 24. Four patients (10%) showed pEVR (>2log drop in HCV RNA) but they failed to achieve negative HCV RNA at the end of the treatment, nineteen patients showed <2log drop of HCV RNA at 12 week. Out these nineteen patients, fifteen patients showed further decrease in HCV viral load at week 24. So this study demonstrated that some patients experienced a partial virological response with NTZ.
Rossignol et al. [16] showed that treatment with NTZ montherapy for patients with CHC genotype 4 at a dose of 500mg orally with food compared with placebo was associated with an ETR at week 24 of (7/23) 30.4% and SVR at week 48 of (4/23) 17.4% compared to 0% for placebo. Whereas, our study reported on EVR of (6/40) 15% and ETR (week 24) of 0%.
These results also confirmed by Mederake [21] who showed that during treatment with NTZ as lead-in phase for 12 week before PEG-INF and RBV, two of 53 patients had a decline of more than 1 Log10 and just one patient achieved a cEVR.
We could find a significant correlation between high baseline viral load and treatment response these results, are in concordance with Kamel et al. [22] Zekri et al. [23] .
Patients who responded to IFN treatment had statistically less number in both transitions and the genetic distances between the quasipseices. So, viral genetic complexity and variability may play a role in the response to IFN treatment. The fibrosis score negatively affected the response to IFN. Treatment and pretreatment viral load didn't affect the outcome of treatment [24] .
Conclusion:
We can conclude that, treatment modalities with PEG-INF, RBV and NTZ is associated with increase in the virological response rates but with no statistically significant difference, monotherapy of CHC patients with NTZ decrease HCV RNA viral load in some patients. Mild side effects were present to NTZ as abdominal pain, nausea, vomiting and urine discoloration and we can recommend double dose of NTZ for improving the response or study the response of NTZ with STAT-S antiviral drugs as teleprevir & bociprevir when they are in our hand.
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